RNAi in Plasmodium

Current Pharmaceutical Design

Volumn 20, Issue 2, 2014, Pages 278-283

  Mueller, Ann Kristin ^b   Hammerschmidt Kamper, Christiane ^b   Kaiser, Annette ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Clinical development; Gene function; Plasmodium; RNAi; SiRNA

Indexed keywords

ANTIPROTOZOAL AGENT; ARGONAUTE PROTEIN; DICER; MICRORNA;

ENTAMOEBA; GENE FUNCTION; GENE IDENTIFICATION; GIARDIA; HUMAN; LEISHMANIA; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOXOPLASMA; TRYPANOSOMA;

ANIMALS; ANTIMALARIALS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; PLASMODIUM; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84892985230     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990027     Document Type: Review

References (54)

1. Kolev NG, Tschudi C, Ullu E, Shi H, Djikeng A, Tschudi C, Ullu E. RNA interference in protozoan parasites: achievements and challenges. Eukaryot Cell 2011; 10: 1156-63.
2. Shi H, Djikeng A, Tschudi C, Ullu E. Argonaute protein in the early divergent eukaryote interfering RNA accumulation and retroposon transcript abundance. Mol Cell Biol 2004; 24: 420-7.
3. Patrick KL, Shi H, Kolev NG, Ersfeld K, Tschudi C, Ullu E. Distinct and overlapping eukaryote Trypanosoma brucei. Proc Natl Acad Sci USA 2009; 20; 106: 17933-8.
4. DaRocha WD, Otsu K, Teixeira SM, Donelson JE. Tests of cytoplasmic RNA interference (RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi. Mol Biochem Parasitol 2004; 133: 175-86.
5. Robinson KA, Beverley SM. Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem Parasitol 2003; 128: 217-28.
6. Baum J, Papenfuss AT, Mair GR, et al. Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. Nucleic Acids Res 2009; 37(11): 3788-98.
7. Lye LF, Owens K, Shi H, et al. Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog 2010; 6: e1001161.
8. Schwentke A, Krepstakies M, Müller AK, et al. In vitro and in vivo silencing of plasmodial dhs and eIF-5A genes in a putative, noncanonical RNAi-related pathway. BMC Microbiol 2012; 12(1): 107.
9. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002; 415 (6872): 686-93.
10. Cowman AF, Baldi DL, Healer J, et al. Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells. FEBS Lett 2000; 476 (1-2): 84-8.
11. Philip N, Orr R, Waters AP. Transfection of rodent malaria parasites. Methods Mol Biol 2013; 923: 99-125.
12. Gardner MJ, Hall N, Fung E et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419: 498-511.
13. Drinnenberg IA, Weinberg DE, Xie KT et al. RNAi in budding yeast. Science 2009; 23; 326: 544-50.
14. Suk K, Choi J, Suzuki Y et al. Reconstitution of human RNA interference in budding yeast. Nucleic Acids Res 2011; 39: e43.
15. MacRae JI, Maréchal E, Biot C, Botté CY. The apicoplast: a key target to cure malaria. Curr Pharm Des, 2012. 18(24): 3490-504.
16. van Dooren GG, Stimmler LM, McFadden GI. Metabolic maps and functions of the Plasmodium mitochondrion. FEMS Microbiol Rev 2006; 30(4): 596-630.
17. McRobert L, McConkey GA. RNA interference (RNAi) inhibits growth of Plasmodium falciparum. Mol Biochem Parasitol 2002; 119(2): 273-8.
18. Malhotra P, Dasaradhi PV, Kumar A, et al. Double-stranded RNAmediated gene silencing of cysteine proteases (falcipain-1 and-2) of Plasmodium falciparum. Mol Microbiol 2002; 45(5): 1245-54.
19. Mohmmed A, Dasaradhi PV, Bhatnagar RK, Chauhan VS, Malhotra P. In vivo gene silencing in Plasmodium berghei--a mouse malaria model. Biochem Biophys Res Commun 2003; 309(3): 506-11.
20. Rathjen T, Nicol C, McConkey G, Dalmay T. Analysis of short RNAs in the malaria parasite and its red blood cell host. FEBS Lett 2006; 580 (22): 5185-8.
21. Xue X, Zhang Q, Huang Y, Feng L, Pan W. No miRNA were found in Plasmodium and the ones identified in erythrocytes could not be correlated with infection. Malar J 2008; 7: 47.
22. Lamonte G, Philip N, Reardon J, et al. Translocation of Sickle Cell Erythrocyte MicroRNAs into Plasmodium falciparum Inhibits Parasite Translation and Contributes to Malaria Resistance. Cell Host Microbe 2012; 12(2): 187-99.
23. Raabe CA, Sanchez CP, Randau G, et al. A global view of the nonprotein-coding transcriptome in Plasmodium falciparum. Nucleic Acids Res 2010; 38(2): 608-17.
24. Prescott EM, Proudfoot NJ. Transcriptional collision between convergent genes in budding yeast. Proc Natl Acad Sci USA 2002; 99(13): 8796-801.
25. Lazar MA, Hodin RA, Cardona G, Chin WW. Gene expression from the c-erbA alpha/Rev-ErbA alpha genomic locus. Potential regulation of alternative splicing by opposite strand transcription. J Biol Chem 1990; 265(22): 12859-63.
26. Tosic M, Roach A, de Rivaz JC, Dolivo M, Matthieu JM. Posttranscriptional events are responsible for low expression of myelin basic protein in myelin deficient mice: role of natural antisense RNA. EMBO J 1990; 9(2): 401-6.
27. Zhang Q, Zhang J, Moe OW, Hsia CC. Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung. Proc Natl Acad Sci USA 2008; 105(21): 7612-7.
28. Sledz CA, Williams BR. RNA interference in biology and disease. Blood 2005; 106(3): 787-94.
29. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-84.
30. Bumcrot D, Manoharan M, Kotealinsky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2: 711-19.
31. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 2003; 9: 210-16.
32. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11: 59-67.
33. Bitko V, Musienko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-5.
34. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5: 834-39.
35. Sen GC. Viruses and interferons. Ann Rev Microbiol 2001; 55: 255-81.
36. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz A, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-4.
37. Schofield L, Grau GE. Immunological processes n malaria pathogenesis. Nat Rev Immunol. 2005; 5 (9): 722-35.
38. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23: 222-6.
39. Lingelbach K, Joiner KA. The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: an unusual compartment in infected cells. J Cell Sci 1998; 111: 1467-75.
40. Gay F, Zougbédé S, N'dilimabaka N, Rebollo A, Mazier D, Moreno A. Cerebral malaria: what is known and what is on research. Rev Neurol (Paris) 2012; 168(3): 239-56.
41. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nano therapeutics for siRNA delivery. J Inter Med 2010; 267: 9-21.
42. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipo-philic siRNAs. Nature Biotech 2007; 25: 1149-57.
43. Pille JY, Li H, Blot E et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nan nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther; 17: 1019-26.
44. de Fougerolles AR. Delivery vehicles for small interferin RNA in vivo. Hum Gene Ther 2008; 19: 125-32.
45. Chernolovskaya EL, Zenkova MA. Chemical modification of siRNA. Curr Opin Mol Ther 2010; 12: 157-67.
46. Hamasaki T et al. Efficacy of a novel class of RNA interference therapeutic agents. PLoS One. 2012; 7(8): e42655.
47. Brown AE, Catteruccia F. Toward silencing the burden of malaria: progress and prospects for RNAi-based approaches 2006; Biotechniques Suppl: 38-44.
48. Brown AE, Bugeon L, Crisanti A, Catteruccia F. Stable and heritable gene silencing in the malaria vector Anopheles stephensi. Nucleic Acids Res 31(15): e85.
49. Blandin S, Shiao SH, Moita LF, et al. Complement-like protein TEP1 is a determinant of vectorial capacity in the malaria vector Anopheles gambiae. Cell 2004; 116(5): 661-70.
50. Osta MA, Christophides GK, Kafatos FC. Effects of mosquito genes on Plasmodium development. Science. 2004; 26; 303(5666): 2030-32.
51. Blandin S, Moita LF, Köcher T, Wilm M, Kafatos FC, Levashina EA. Reverse genetics in the mosquito Anopheles gambiae: targeted disruption of the Defensin gene. Embo Reports 2002; 3(9): 852-56.
52. Pharmacokinetics. (2006). In Mosby's Dictionary of Medicine, Nursing, & Health Professions. Philadelphia, PA: Elsevier Health Sciences. Retrieved December 11, 2008, from http://www. credoreference. com/entry/6686418.
53. Tonkin CJ, Kalanon M, McFadden GI. Protein targeting to the malaria parasite plastid. Traffic 2008; 9(2): 166-75.
54. Bender A, van Dooren GG, Ralph SA, McFadden GI, Schneider G. Properties and prediction of mitochondrial transit peptides from Plasmodium falciparum. Mol Biochem Parasitol 2003; 132(2): 59-66.